OncoMatch/Clinical Trials/NCT05632809
REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)
Is NCT05632809 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including NKTR-255 and Durvalumab for lung cancer.
Treatment: NKTR-255 · Durvalumab — To learn about the effects of the investigational drug NKTR-255 in combination with the standard drug durvalumab on locally advanced NSCLC when given after CRT.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anti-PD-1 therapy
Prior exposure to any anti-PD-1 or anti-PD-L1 antibody.
Cannot have received: anti-PD-L1 therapy
Prior exposure to any anti-PD-1 or anti-PD-L1 antibody.
Cannot have received: IL-2
Prior exposure to IL-2 or IL-5.
Cannot have received: IL-5
Prior exposure to IL-2 or IL-5.
Lab requirements
Kidney function
cr < 2.5 limit of normal and cr clearance >30
Liver function
ast, alt, alk phos, and tbili <2 fold upper limit
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05632809 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy, anti-PD-L1 therapy, IL-2 disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify